What is the current stock price of Nektar Therapeutics (NKTR)?

As of the latest market data, Nektar Therapeutics (NKTR) is trading at $77.50. The stock has seen a loss of -0.45% today.

Does Nektar Therapeutics (NKTR) pay a dividend?

Based on current data, Nektar Therapeutics does not have a confirmed active dividend policy.

What is the market cap of Nektar Therapeutics?

The current market capitalization of Nektar Therapeutics (NKTR) is approximately unavailable.

NKTR

Nektar Therapeutics·Healthcare

77.50

0.450%(−0.35)

Market Closed

78.66

1.497%(+1.16)

After Hours

Last Updated: — ET

52W L: $7.9952W H: $78.95

NKTR NEWS

newsfilecorp.com

9h ago

NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

globenewswire.com

1d ago

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 25, 2025, both dates inclusive (the “Class Period”).

globenewswire.com

1d ago

NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With Losses May Join – The Gross Law Firm

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).

prnewswire.com

1d ago

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

prnewswire.com

2d ago

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. So what: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

prnewswire.com

2d ago

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, April 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit.

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1994-05-03

Beta

1.18

Websitewww.nektar.com↗